xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06015698</url>
    </required_header>
    <id_info>
      <org_study_id>10</org_study_id>
      <nct_id>NCT06015698</nct_id>
    </id_info>
    <brief_title>Laparoscopic Tubal Disconnection Versus Laparoscopic Salpingectomy in Infertile Patients</brief_title>
    <official_title>Laparoscopic Tubal Disconnection Versus Laparoscopic Salpingectomy in Infertile Patients Scheduled for IVF/ICSI. Randomized Controlled Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Ain Shams Maternity Hospital</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Ain Shams Maternity Hospital</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Tubal factor infertility is known to be one of the most common indications for IVF treatment.&#xD;
        Patients with hydrosalpinges have been identified to have poor pregnancy outcomes such as&#xD;
        lower implantation and pregnancy rates &amp; higher rates of spontaneous abortion and ectopic&#xD;
        pregnancies. Surgical intervention can be recommended for patients with hydrosalpinx prior to&#xD;
        IVF/ICSI.&#xD;
  &#xD;
        This study will be done at Ain Shams University Maternity Hospital, to compare laparoscopic&#xD;
        salpingectomy &amp; laparoscopic tubal disconnection as two surgical modalities of treatment of&#xD;
        unilateral or bilateral hydrosalpinges in women older than 30 years and scheduled for&#xD;
        IVF/ICSI, regarding implantation rates, clinical pregnancy rates, ongoing pregnancy rates,&#xD;
        ectopic pregnancy rates, and operative complications.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        It is estimated that tubal factors account for 14% of the causes of subfertility in women.&#xD;
        The prevalence of hydrosalpinx among tubal diseases is as high as 30% of couples presenting&#xD;
        with infertility from tubal factors.&#xD;
  &#xD;
        Hydrosalpinx is the dilation of the fallopian tube in the presence of distal tubal occlusion,&#xD;
        which may result from several causes. The leading cause of distal tubal occlusion is pelvic&#xD;
        inflammatory disease (PID), usually resulting from a prior sexually transmitted disease, such&#xD;
        as Chlamydia trachomatis or Neisseria gonorrhoeae. Tubal tuberculosis is an uncommon cause of&#xD;
        hydrosalpinx, though re-emerging in developed countries. Other etiologies include&#xD;
        endometriosis, appendicitis, and abdominopelvic surgery.&#xD;
  &#xD;
        Depending on several patient factors, tubal microsurgery, or more commonly IVF with its&#xD;
        improving success rates, are the recommended treatment options for tubal factor infertility.&#xD;
  &#xD;
        In addition to its essential role in infertility, hydrosalpinx has an adverse effect on the&#xD;
        outcome of in vitro fertilization (IVF) Hydrosalpinx can decrease the clinical pregnancy rate&#xD;
        of IVF-ET, and increase the incidence of abortion and ectopic pregnancy.&#xD;
  &#xD;
        The presence of hydrosalpinx has a negative effect on IVF/ET because of the suspected&#xD;
        embryotoxicity of the hydrosalpingeal fluid due to a combination of mechanical and chemical&#xD;
        factors thought to disrupt the endometrial environment.&#xD;
  &#xD;
        Surgical treatment should be considered for all women with hydrosalpinges prior to IVF&#xD;
        treatment (Johnson et al .,2004 )&#xD;
  &#xD;
        Removing (salpingectomy) or occluding blocked or diseased fallopian tubes before IVF can&#xD;
        increase pregnancy and live birth rates for women on the IVF program.&#xD;
  &#xD;
        A network meta-analysis showed that Proximal tubal occlusion, salpingectomy, and aspiration&#xD;
        for treatment of hydrosalpinx scored consistently better than did no intervention for the&#xD;
        outcome of IVF/ET. Tubal occlusion and salpingectomy also improve ongoing pregnancy rates.&#xD;
        Proximal tubal occlusion ranks highest for most of the outcomes assessed, whereas no&#xD;
        intervention scores consistently as the least effective strategy for all outcomes&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 30, 2023</start_date>
    <completion_date type="Anticipated">August 30, 2024</completion_date>
    <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Ongoing pregnancy rate</measure>
      <time_frame>From 10 + 0 weeks of gestation</time_frame>
      <description>Pregnancy with detectable heart beat 10weeks gestation or beyond</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Operative time</measure>
      <time_frame>in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity</time_frame>
      <description>in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Intraoperative complications</measure>
      <time_frame>During the procedure</time_frame>
      <description>Bowel injury - Vascular injury</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Postoperative complications</measure>
      <time_frame>First 48 hours after the procedure</time_frame>
      <description>ileus - surgical emphysema</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">150</enrollment>
    <condition>Infertility, Female</condition>
    <arm_group>
      <arm_group_label>Tubal disconnection</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated&#xD;
  The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently&#xD;
  The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow&#xD;
  Then, the tube is severed in the middle of the burn area with laparoscopic scissors&#xD;
  Ensure adequate hemostasis</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Salpingectomy</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>The tube will be removed from its anatomical attachements by progressive bipolar coagulation&#xD;
  Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors&#xD;
  Removal of the tube through one of the ancillary ports using artery forceps&#xD;
  Ensure adequate hemostasis</description>
    </arm_group>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>Laparoscopic tubal disconnection</intervention_name>
      <description>The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated&#xD;
  The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently&#xD;
  The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow&#xD;
  Then, the tube is severed in the middle of the burn area with laparoscopic scissors&#xD;
  Ensure adequate hemostasis</description>
      <arm_group_label>Tubal disconnection</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>Laparoscopic salpingectomy</intervention_name>
      <description>The tube will be removed from its anatomical attachements by progressive bipolar coagulation&#xD;
  Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors&#xD;
  Removal of the tube through one of the ancillary ports using artery forceps&#xD;
  Ensure adequate hemostasis</description>
      <arm_group_label>Salpingectomy</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Infertile ( primary or secondary ).&#xD;
  &#xD;
            2. Age &gt; 30 years .&#xD;
  &#xD;
            3. HSG with unilateral or bilateral hydrosaalpinx , confirmed laparoscopically.&#xD;
  &#xD;
            4. Scheduled for IVF/ICSI&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Contraindications for laparoscopy&#xD;
  &#xD;
                 -  Cardiac disease.&#xD;
  &#xD;
                 -  BMI &gt; 40 kg/m²&#xD;
  &#xD;
                 -  Previous midline incision .&#xD;
  &#xD;
                 -  Past history of TB peritonitis .&#xD;
  &#xD;
            2. Proximal tubal block by HCG .&#xD;
  &#xD;
            3. Frozen pelvis proved by previous laparoscopy or laparotomy .&#xD;
  &#xD;
            4. Allergy to contrast media of HSG .&#xD;
  &#xD;
            5. Premature ovarian failure (Serum FSH &gt;40 mIU/ml )&#xD;
  &#xD;
            6. Prescence of Male factor contributing to the infertility proved by abnormal semen&#xD;
               analysis&#xD;
  &#xD;
            7. Prescence of Ovarian factor contributing to the infertility proved by the prescence of&#xD;
               features suggesting anovulation&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>30 Years</minimum_age>
      <maximum_age>40 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Hamdy B Alqenawy, M.D.,</last_name>
      <role>Study Director</role>
      <affiliation>Ain Shams university - Faculty of Medicine</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Ahmed G Abd Elrahim, M.D.,</last_name>
      <role>Principal Investigator</role>
      <affiliation>Ain Shams university - Faculty of Medicine</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Alaa S Elsewafy, M.D.,</last_name>
      <role>Principal Investigator</role>
      <affiliation>Ain Shams university - Faculty of Medicine</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Ahmed M Elmaraghy, M.D.,</last_name>
      <phone>01010370980</phone>
      <email>amam85@outlook.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Ahmed Sewidan, M.D.,</last_name>
      <phone>01223733849</phone>
      <email>Ahmed.Sewidan@med.suezuni.edu.eg</email>
    </overall_contact_backup>
    <reference>
      <citation>Ajonuma LC, Ng EH, Chan HC. New insights into the mechanisms underlying hydrosalpinx fluid formation and its adverse effect on IVF outcome. Hum Reprod Update. 2002 May-Jun;8(3):255-64. doi: 10.1093/humupd/8.3.255.</citation>
      <PMID>12078836</PMID>
    </reference>
    <reference>
      <citation>D'Arpe S, Franceschetti S, Caccetta J, Pietrangeli D, Muzii L, Panici PB. Management of hydrosalpinx before IVF: a literature review. J Obstet Gynaecol. 2015;35(6):547-50. doi: 10.3109/01443615.2014.985768. Epub 2014 Dec 1.</citation>
      <PMID>25436898</PMID>
    </reference>
    <reference>
      <citation>Dreyer K, Lier MC, Emanuel MH, Twisk JW, Mol BW, Schats R, Hompes PG, Mijatovic V. Hysteroscopic proximal tubal occlusion versus laparoscopic salpingectomy as a treatment for hydrosalpinges prior to IVF or ICSI: an RCT. Hum Reprod. 2016 Sep;31(9):2005-16. doi: 10.1093/humrep/dew050. Epub 2016 May 21.</citation>
      <PMID>27209341</PMID>
    </reference>
    <reference>
      <citation>Dun EC, Nezhat CH. Tubal factor infertility: diagnosis and management in the era of assisted reproductive technology. Obstet Gynecol Clin North Am. 2012 Dec;39(4):551-66. doi: 10.1016/j.ogc.2012.09.006.</citation>
      <PMID>23182560</PMID>
    </reference>
    <reference>
      <citation>Hong X, Ding WB, Yuan RF, Ding JY, Jin J. Effect of interventional embolization treatment for hydrosalpinx on the outcome of in vitro fertilization and embryo transfer. Medicine (Baltimore). 2018 Nov;97(48):e13143. doi: 10.1097/MD.0000000000013143.</citation>
      <PMID>30508891</PMID>
    </reference>
    <reference>
      <citation>Johnson N, van Voorst S, Sowter MC, Strandell A, Mol BW. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD002125. doi: 10.1002/14651858.CD002125.pub3.</citation>
      <PMID>20091531</PMID>
    </reference>
    <reference>
      <citation>Nackley AC, Muasher SJ. The significance of hydrosalpinx in in vitro fertilization. Fertil Steril. 1998 Mar;69(3):373-84. doi: 10.1016/s0015-0282(97)00484-6.</citation>
      <PMID>9531862</PMID>
    </reference>
    <reference>
      <citation>National Collaborating Centre for Women's and Children's Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London: Royal College of Obstetricians &amp; Gynaecologists; 2013 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK247932/</citation>
      <PMID>25340218</PMID>
    </reference>
    <reference>
      <citation>Ng KYB, Cheong Y. Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion. Best Pract Res Clin Obstet Gynaecol. 2019 Aug;59:41-47. doi: 10.1016/j.bpobgyn.2019.01.011. Epub 2019 Jan 29.</citation>
      <PMID>30824209</PMID>
    </reference>
    <reference>
      <citation>Strandell A. The influence of hydrosalpinx on IVF and embryo transfer: a review. Hum Reprod Update. 2000 Jul-Aug;6(4):387-95. doi: 10.1093/humupd/6.4.387.</citation>
      <PMID>10972525</PMID>
    </reference>
    <reference>
      <citation>Tsiami A, Chaimani A, Mavridis D, Siskou M, Assimakopoulos E, Sotiriadis A. Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis. Ultrasound Obstet Gynecol. 2016 Oct;48(4):434-445. doi: 10.1002/uog.15900. Epub 2016 Sep 13.</citation>
      <PMID>26922863</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 23, 2023</study_first_submitted>
    <study_first_submitted_qc>August 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 29, 2023</study_first_posted>
    <last_update_submitted>August 23, 2023</last_update_submitted>
    <last_update_submitted_qc>August 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 29, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
      <investigator_full_name>Ahmed Mohammed Elmaraghy</investigator_full_name>
      <investigator_title>Lecturer in Obstetrics and Gynecology</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Infertility</mesh_term>
      <mesh_term>Infertility, Female</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06015698
  org study id: 10
  nct id: NCT06015698
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  Tubal factor infertility is known to be one of the most common indications for IVF treatment.
        Patients with hydrosalpinges have been identified to have poor pregnancy outcomes such as
        lower implantation and pregnancy rates & higher rates of spontaneous abortion and ectopic
        pregnancies. Surgical intervention can be recommended for patients with hydrosalpinx prior to
        IVF/ICSI.
  
        This study will be done at Ain Shams University Maternity Hospital, to compare laparoscopic
        salpingectomy & laparoscopic tubal disconnection as two surgical modalities of treatment of
        unilateral or bilateral hydrosalpinges in women older than 30 years and scheduled for
        IVF/ICSI, regarding implantation rates, clinical pregnancy rates, ongoing pregnancy rates,
        ectopic pregnancy rates, and operative complications.
  It is estimated that tubal factors account for 14% of the causes of subfertility in women.
        The prevalence of hydrosalpinx among tubal diseases is as high as 30% of couples presenting
        with infertility from tubal factors.
  
        Hydrosalpinx is the dilation of the fallopian tube in the presence of distal tubal occlusion,
        which may result from several causes. The leading cause of distal tubal occlusion is pelvic
        inflammatory disease (PID), usually resulting from a prior sexually transmitted disease, such
        as Chlamydia trachomatis or Neisseria gonorrhoeae. Tubal tuberculosis is an uncommon cause of
        hydrosalpinx, though re-emerging in developed countries. Other etiologies include
        endometriosis, appendicitis, and abdominopelvic surgery.
  
        Depending on several patient factors, tubal microsurgery, or more commonly IVF with its
        improving success rates, are the recommended treatment options for tubal factor infertility.
  
        In addition to its essential role in infertility, hydrosalpinx has an adverse effect on the
        outcome of in vitro fertilization (IVF) Hydrosalpinx can decrease the clinical pregnancy rate
        of IVF-ET, and increase the incidence of abortion and ectopic pregnancy.
  
        The presence of hydrosalpinx has a negative effect on IVF/ET because of the suspected
        embryotoxicity of the hydrosalpingeal fluid due to a combination of mechanical and chemical
        factors thought to disrupt the endometrial environment.
  
        Surgical treatment should be considered for all women with hydrosalpinges prior to IVF
        treatment (Johnson et al .,2004 )
  
        Removing (salpingectomy) or occluding blocked or diseased fallopian tubes before IVF can
        increase pregnancy and live birth rates for women on the IVF program.
  
        A network meta-analysis showed that Proximal tubal occlusion, salpingectomy, and aspiration
        for treatment of hydrosalpinx scored consistently better than did no intervention for the
        outcome of IVF/ET. Tubal occlusion and salpingectomy also improve ongoing pregnancy rates.
        Proximal tubal occlusion ranks highest for most of the outcomes assessed, whereas no
        intervention scores consistently as the least effective strategy for all outcomes
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Double (Participant, Investigator)
  measure: Ongoing pregnancy rate
  time frame: From 10 + 0 weeks of gestation
  description: Pregnancy with detectable heart beat 10weeks gestation or beyond
  measure: Operative time
  time frame: in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity
  description: in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity
  measure: Intraoperative complications
  time frame: During the procedure
  description: Bowel injury - Vascular injury
  measure: Postoperative complications
  time frame: First 48 hours after the procedure
  description: ileus - surgical emphysema
  arm group label: Tubal disconnection
  arm group type: Experimental
  description: The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated
  The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently
  The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow
  Then, the tube is severed in the middle of the burn area with laparoscopic scissors
  Ensure adequate hemostasis
  arm group label: Salpingectomy
  arm group type: Active Comparator
  description: The tube will be removed from its anatomical attachements by progressive bipolar coagulation
  Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors
  Removal of the tube through one of the ancillary ports using artery forceps
  Ensure adequate hemostasis
  intervention type: Procedure
  intervention name: Laparoscopic tubal disconnection
  description: The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated
  The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently
  The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow
  Then, the tube is severed in the middle of the burn area with laparoscopic scissors
  Ensure adequate hemostasis
  arm group label: Tubal disconnection
  intervention type: Procedure
  intervention name: Laparoscopic salpingectomy
  description: The tube will be removed from its anatomical attachements by progressive bipolar coagulation
  Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors
  Removal of the tube through one of the ancillary ports using artery forceps
  Ensure adequate hemostasis
  arm group label: Salpingectomy
  criteria: 
  gender: Female
  minimum age: 30 Years
  maximum age: 40 Years
  healthy volunteers: No
  last name: Hamdy B Alqenawy, M.D.,
  role: Study Director
  affiliation: Ain Shams university - Faculty of Medicine
  last name: Ahmed G Abd Elrahim, M.D.,
  role: Principal Investigator
  affiliation: Ain Shams university - Faculty of Medicine
  last name: Alaa S Elsewafy, M.D.,
  role: Principal Investigator
  affiliation: Ain Shams university - Faculty of Medicine
  last name: Ahmed M Elmaraghy, M.D.,
  phone: 01010370980
  email: amam85@outlook.com
  last name: Ahmed Sewidan, M.D.,
  phone: 01223733849
  email: Ahmed.Sewidan@med.suezuni.edu.eg
  citation: Ajonuma LC, Ng EH, Chan HC. New insights into the mechanisms underlying hydrosalpinx fluid formation and its adverse effect on IVF outcome. Hum Reprod Update. 2002 May-Jun;8(3):255-64. doi: 10.1093/humupd/8.3.255.
  PMID: 12078836
  citation: D'Arpe S, Franceschetti S, Caccetta J, Pietrangeli D, Muzii L, Panici PB. Management of hydrosalpinx before IVF: a literature review. J Obstet Gynaecol. 2015;35(6):547-50. doi: 10.3109/01443615.2014.985768. Epub 2014 Dec 1.
  PMID: 25436898
  citation: Dreyer K, Lier MC, Emanuel MH, Twisk JW, Mol BW, Schats R, Hompes PG, Mijatovic V. Hysteroscopic proximal tubal occlusion versus laparoscopic salpingectomy as a treatment for hydrosalpinges prior to IVF or ICSI: an RCT. Hum Reprod. 2016 Sep;31(9):2005-16. doi: 10.1093/humrep/dew050. Epub 2016 May 21.
  PMID: 27209341
  citation: Dun EC, Nezhat CH. Tubal factor infertility: diagnosis and management in the era of assisted reproductive technology. Obstet Gynecol Clin North Am. 2012 Dec;39(4):551-66. doi: 10.1016/j.ogc.2012.09.006.
  PMID: 23182560
  citation: Hong X, Ding WB, Yuan RF, Ding JY, Jin J. Effect of interventional embolization treatment for hydrosalpinx on the outcome of in vitro fertilization and embryo transfer. Medicine (Baltimore). 2018 Nov;97(48):e13143. doi: 10.1097/MD.0000000000013143.
  PMID: 30508891
  citation: Johnson N, van Voorst S, Sowter MC, Strandell A, Mol BW. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD002125. doi: 10.1002/14651858.CD002125.pub3.
  PMID: 20091531
  citation: Nackley AC, Muasher SJ. The significance of hydrosalpinx in in vitro fertilization. Fertil Steril. 1998 Mar;69(3):373-84. doi: 10.1016/s0015-0282(97)00484-6.
  PMID: 9531862
  citation: National Collaborating Centre for Women's and Children's Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London: Royal College of Obstetricians & Gynaecologists; 2013 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK247932/
  PMID: 25340218
  citation: Ng KYB, Cheong Y. Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion. Best Pract Res Clin Obstet Gynaecol. 2019 Aug;59:41-47. doi: 10.1016/j.bpobgyn.2019.01.011. Epub 2019 Jan 29.
  PMID: 30824209
  citation: Strandell A. The influence of hydrosalpinx on IVF and embryo transfer: a review. Hum Reprod Update. 2000 Jul-Aug;6(4):387-95. doi: 10.1093/humupd/6.4.387.
  PMID: 10972525
  citation: Tsiami A, Chaimani A, Mavridis D, Siskou M, Assimakopoulos E, Sotiriadis A. Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis. Ultrasound Obstet Gynecol. 2016 Oct;48(4):434-445. doi: 10.1002/uog.15900. Epub 2016 Sep 13.
  PMID: 26922863
  responsible party type: Principal Investigator
  investigator affiliation: Ain Shams Maternity Hospital
  investigator full name: Ahmed Mohammed Elmaraghy
  investigator title: Lecturer in Obstetrics and Gynecology
  mesh term: Infertility
  mesh term: Infertility, Female